A recent randomized clinical trial has found that men with localized, intermediate-risk prostate cancer recovered faster and experienced less short-term impact on their daily lives when treated with MRI-guided, transurethral ultrasound ablation (TULSA) compared with robotic prostate surgery. The results of the CAPTAIN Trial were presented at the SIR 2026 Annual Scientific Meeting in Toronto. The work is published in the Journal of Vascular and Interventional Radiology.
This article was originally published on MedicalXpress.com

